Primary Biliary Cholangitis Treatment
Primary Biliary Cholangitis Treatment

Primary Biliary Cholangitis Treatment Comprehensive Study by Drug Type (Ursodeoxycholic acid (UDCA), Obeticholic acid (Ocaliva), Corticosteroids, Methotrexate, Others), Blood Test (Blood test, Liver test, Cholesterol test) Players and Region - Global Market Outlook to 2026

Primary Biliary Cholangitis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 215 Pages 188 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Primary biliary cholangitis, also known as primary biliary cirrhosis, is a condition that affects the ability of the liver to function properly. Itís chronic, which means it lasts a long period or comes back on a frequent basis. In COVID-19, In many countries and healthcare systems have been, or still are, affecting by this pandemic, which is significantly impacting the care of these patients. PBC is most commonly diagnosed in persons between the ages of 35 and 60. Women account for more than 90% of PBC patients. It has an impact on people of all races. PBC affects roughly 65 out of every 100,000 women and 12 out of every 100,000 men.

Market Drivers
  • Increase in research and development activities for the development of medication
  • Increased the availability of treatment services and drugs
  • Increasing pipeline studies to develop prominent treatments for Primary biliary cholangitis


Restraints
  • Lack of definitive treatment for the disease

Opportunities
Increase in approvals of drugs to treat PBC by Food and Drug Administration

Players Covered in the Study are:
Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Retrophin, Inc., Calliditas Therapeutics AB. and Axcan Scandipharm Inc.

The Global Primary Biliary Cholangitis Treatment market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

What can be explored with Primary Biliary Cholangitis Treatment study:
• Where Primary Biliary Cholangitis Treatment industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are GlaxoSmithKline (GSK) pharmaceutical (UK), Epic Pharma, LLC (United States) and Mylan Pharmaceuticals Inc. (United States).


Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Primary Biliary Cholangitis Treatment Market?
The Primary Biliary Cholangitis Treatment market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Primary Biliary Cholangitis Treatment Market?
Top performing companies in the Global Primary Biliary Cholangitis Treatment market are Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Retrophin, Inc., Calliditas Therapeutics AB. and Axcan Scandipharm Inc., to name a few.

3. What trending factors would impact Primary Biliary Cholangitis Treatment Market growth most?
"" is seen as one of major influencing trends for Primary Biliary Cholangitis Treatment Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Drug Type
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • Corticosteroids
  • Methotrexate
  • Others

By Blood Test
  • Blood test
  • Liver test
  • Cholesterol test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in research and development activities for the development of medication
      • 3.2.2. Increased the availability of treatment services and drugs
      • 3.2.3. Increasing pipeline studies to develop prominent treatments for Primary biliary cholangitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Biliary Cholangitis Treatment, by Drug Type, Blood Test and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primary Biliary Cholangitis Treatment (Value)
      • 5.2.1. Global Primary Biliary Cholangitis Treatment by: Drug Type (Value)
        • 5.2.1.1. Ursodeoxycholic acid (UDCA)
        • 5.2.1.2. Obeticholic acid (Ocaliva)
        • 5.2.1.3. Corticosteroids
        • 5.2.1.4. Methotrexate
        • 5.2.1.5. Others
      • 5.2.2. Global Primary Biliary Cholangitis Treatment Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Primary Biliary Cholangitis Treatment (Price)
  • 6. Primary Biliary Cholangitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. NGM Biopharmaceuticals
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lumena Pharmaceuticals, Inc.
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. TARGET PharmaSolutions, Inc.
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Intercept Pharmaceuticals, Inc.
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Retrophin, Inc.
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Calliditas Therapeutics AB.
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Axcan Scandipharm Inc.
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Primary Biliary Cholangitis Treatment Sale, by Drug Type, Blood Test and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primary Biliary Cholangitis Treatment (Value)
      • 7.2.1. Global Primary Biliary Cholangitis Treatment by: Drug Type (Value)
        • 7.2.1.1. Ursodeoxycholic acid (UDCA)
        • 7.2.1.2. Obeticholic acid (Ocaliva)
        • 7.2.1.3. Corticosteroids
        • 7.2.1.4. Methotrexate
        • 7.2.1.5. Others
      • 7.2.2. Global Primary Biliary Cholangitis Treatment Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Primary Biliary Cholangitis Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Biliary Cholangitis Treatment: by Drug Type(USD Million)
  • Table 2. Primary Biliary Cholangitis Treatment Ursodeoxycholic acid (UDCA) , by Region USD Million (2015-2020)
  • Table 3. Primary Biliary Cholangitis Treatment Obeticholic acid (Ocaliva) , by Region USD Million (2015-2020)
  • Table 4. Primary Biliary Cholangitis Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 5. Primary Biliary Cholangitis Treatment Methotrexate , by Region USD Million (2015-2020)
  • Table 6. Primary Biliary Cholangitis Treatment Others , by Region USD Million (2015-2020)
  • Table 7. South America Primary Biliary Cholangitis Treatment, by Country USD Million (2015-2020)
  • Table 8. South America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 9. South America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 10. Brazil Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 11. Brazil Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 12. Argentina Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 13. Argentina Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 14. Rest of South America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 15. Rest of South America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 16. Asia Pacific Primary Biliary Cholangitis Treatment, by Country USD Million (2015-2020)
  • Table 17. Asia Pacific Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 18. Asia Pacific Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 19. China Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 20. China Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 21. Japan Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 22. Japan Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 23. India Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 24. India Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 25. South Korea Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 26. South Korea Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 27. Taiwan Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 28. Taiwan Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 29. Australia Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 30. Australia Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 31. Rest of Asia-Pacific Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 32. Rest of Asia-Pacific Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 33. Europe Primary Biliary Cholangitis Treatment, by Country USD Million (2015-2020)
  • Table 34. Europe Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 35. Europe Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 36. Germany Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 37. Germany Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 38. France Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 39. France Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 40. Italy Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 41. Italy Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 42. United Kingdom Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 43. United Kingdom Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 44. Netherlands Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 45. Netherlands Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 46. Rest of Europe Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 47. Rest of Europe Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 48. MEA Primary Biliary Cholangitis Treatment, by Country USD Million (2015-2020)
  • Table 49. MEA Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 50. MEA Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 51. Middle East Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 52. Middle East Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 53. Africa Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 54. Africa Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 55. North America Primary Biliary Cholangitis Treatment, by Country USD Million (2015-2020)
  • Table 56. North America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 57. North America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 58. United States Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 59. United States Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 60. Canada Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 61. Canada Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 62. Mexico Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2015-2020)
  • Table 63. Mexico Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2015-2020)
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Primary Biliary Cholangitis Treatment: by Drug Type(USD Million)
  • Table 74. Primary Biliary Cholangitis Treatment Ursodeoxycholic acid (UDCA) , by Region USD Million (2021-2026)
  • Table 75. Primary Biliary Cholangitis Treatment Obeticholic acid (Ocaliva) , by Region USD Million (2021-2026)
  • Table 76. Primary Biliary Cholangitis Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 77. Primary Biliary Cholangitis Treatment Methotrexate , by Region USD Million (2021-2026)
  • Table 78. Primary Biliary Cholangitis Treatment Others , by Region USD Million (2021-2026)
  • Table 79. South America Primary Biliary Cholangitis Treatment, by Country USD Million (2021-2026)
  • Table 80. South America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 81. South America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 82. Brazil Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 83. Brazil Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 84. Argentina Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 85. Argentina Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 86. Rest of South America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 87. Rest of South America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 88. Asia Pacific Primary Biliary Cholangitis Treatment, by Country USD Million (2021-2026)
  • Table 89. Asia Pacific Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 90. Asia Pacific Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 91. China Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 92. China Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 93. Japan Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 94. Japan Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 95. India Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 96. India Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 97. South Korea Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 98. South Korea Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 99. Taiwan Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 100. Taiwan Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 101. Australia Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 102. Australia Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 103. Rest of Asia-Pacific Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 104. Rest of Asia-Pacific Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 105. Europe Primary Biliary Cholangitis Treatment, by Country USD Million (2021-2026)
  • Table 106. Europe Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 107. Europe Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 108. Germany Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 109. Germany Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 110. France Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 111. France Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 112. Italy Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 113. Italy Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 114. United Kingdom Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 115. United Kingdom Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 116. Netherlands Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 117. Netherlands Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 118. Rest of Europe Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 119. Rest of Europe Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 120. MEA Primary Biliary Cholangitis Treatment, by Country USD Million (2021-2026)
  • Table 121. MEA Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 122. MEA Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 123. Middle East Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 124. Middle East Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 125. Africa Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 126. Africa Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 127. North America Primary Biliary Cholangitis Treatment, by Country USD Million (2021-2026)
  • Table 128. North America Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 129. North America Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 130. United States Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 131. United States Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 132. Canada Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 133. Canada Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 134. Mexico Primary Biliary Cholangitis Treatment, by Drug Type USD Million (2021-2026)
  • Table 135. Mexico Primary Biliary Cholangitis Treatment, by Blood Test USD Million (2021-2026)
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Biliary Cholangitis Treatment: by Drug Type USD Million (2015-2020)
  • Figure 5. South America Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 6. Asia Pacific Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 7. Europe Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 8. MEA Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 9. North America Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 10. Global Primary Biliary Cholangitis Treatment share by Players 2020 (%)
  • Figure 11. Global Primary Biliary Cholangitis Treatment share by Players (Top 3) 2020(%)
  • Figure 12. Global Primary Biliary Cholangitis Treatment share by Players (Top 5) 2020(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Novartis AG Revenue, Net Income and Gross profit
  • Figure 15. Novartis AG Revenue: by Geography 2020
  • Figure 16. Bristol-Myers Squibb Revenue, Net Income and Gross profit
  • Figure 17. Bristol-Myers Squibb Revenue: by Geography 2020
  • Figure 18. NGM Biopharmaceuticals Revenue, Net Income and Gross profit
  • Figure 19. NGM Biopharmaceuticals Revenue: by Geography 2020
  • Figure 20. Lumena Pharmaceuticals, Inc. Revenue, Net Income and Gross profit
  • Figure 21. Lumena Pharmaceuticals, Inc. Revenue: by Geography 2020
  • Figure 22. TARGET PharmaSolutions, Inc. Revenue, Net Income and Gross profit
  • Figure 23. TARGET PharmaSolutions, Inc. Revenue: by Geography 2020
  • Figure 24. Intercept Pharmaceuticals, Inc. Revenue, Net Income and Gross profit
  • Figure 25. Intercept Pharmaceuticals, Inc. Revenue: by Geography 2020
  • Figure 26. Retrophin, Inc. Revenue, Net Income and Gross profit
  • Figure 27. Retrophin, Inc. Revenue: by Geography 2020
  • Figure 28. Calliditas Therapeutics AB. Revenue, Net Income and Gross profit
  • Figure 29. Calliditas Therapeutics AB. Revenue: by Geography 2020
  • Figure 30. Axcan Scandipharm Inc. Revenue, Net Income and Gross profit
  • Figure 31. Axcan Scandipharm Inc. Revenue: by Geography 2020
  • Figure 32. Global Primary Biliary Cholangitis Treatment: by Drug Type USD Million (2021-2026)
  • Figure 33. South America Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 34. Asia Pacific Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 35. Europe Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 36. MEA Primary Biliary Cholangitis Treatment Share (%), by Country
  • Figure 37. North America Primary Biliary Cholangitis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis AG
  • Bristol-Myers Squibb
  • NGM Biopharmaceuticals
  • Lumena Pharmaceuticals, Inc.
  • TARGET PharmaSolutions, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Retrophin, Inc.
  • Calliditas Therapeutics AB.
  • Axcan Scandipharm Inc.
Additional players considered in the study are as follows:
GlaxoSmithKline (GSK) pharmaceutical (UK) , Epic Pharma, LLC (United States) , Mylan Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation